Justin Kanoff, MD
Retina Specialist · Longmont, CONPI 1326205048
Payments from drug & device makers
Across 145 payments — averaging $96.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$10K
- Genentech USA, Inc.$558
- Rxsight Inc$497
- Regeneron Healthcare Solutions, Inc.$486
- Genentech, Inc.$330
- Alcon$330
- plus $2K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 2 | $9,500 |
| Genentech USA, Inc. | 13 | $558 |
| Rxsight Inc | 4 | $497 |
| Regeneron Healthcare Solutions, Inc. | 19 | $486 |
| Genentech, Inc. | 15 | $330 |
| Alcon | 12 | $330 |
| Notal Vision, Inc. | 3 | $281 |
| Apellis Pharmaceuticals, Inc. | 11 | $261 |
| AbbVie(2 entities) | 13 | $201 |
| Novartis | 5 | $179 |
| Alimera Sciences, Inc. | 9 | $158 |
| Omeros Corporation | 2 | $142 |
| Dompe US, Inc. | 1 | $131 |
| Glaukos Corporation | 5 | $111 |
| Beaver-visitec International, Inc. | 1 | $102 |
| Carl Zeiss Meditec, Inc. | 1 | $95 |
| Bausch & Lomb Americas Inc. | 4 | $92 |
| Astellas Pharma US Inc | 3 | $80 |
| Biogen | 4 | $76 |
| Optos, Inc. | 3 | $56 |
| Coherus Oncology, Inc. | 2 | $41 |
| Harrow Eye, LLC | 2 | $38 |
| Spark Therapeutics, Inc. | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Eyepoint US, Inc. | 1 | $21 |
| Ocular Therapeutix, Inc. | 1 | $18 |
| Lumibird Medical Inc. | 1 | $17 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $11 |
How this compares
$13,930 in reported general payments places this provider in the 50th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Longmont
- Carl NobleLongmont$336K
- Matthew ManryLongmont$225K
- William BenedictLongmont$599
- Sara HaugDurango$9.5M
- James LuuColorado Springs$2.9M
- Mimi LiuEnglewood$2.2M
- Murtaza AdamParker$2.1M
- Ramin SarrafizadehColorado Springs$1.7M
- Brian JoondephDenver$1.6M
- Mark ChittumColorado Springs$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.